(Total Views: 273)
Posted On: 09/08/2017 5:00:06 PM
Post# of 72447
Very happy to see presentation followed what a few knowledgeable posters told us it should to preserve the double-blind status of the trials. No new info regarding B(OM) or P but that was expected. I don't really think the interim data from P projected for later this month will go much beyond what this presentation said about the ongoing trial.
Glad to see P and B(OM) targeted for Q4 completion while K is going to be a little later in 2018 (at least that is the way I interpreted the K data). The presentation said some data would be available prior to 2018 but could the company state any numerical data prior to top line results? Not sure about this one point.
No puff, no overhype, just basic, professional presentation that should raise the status of IPIX in the financial community.
Glad to see P and B(OM) targeted for Q4 completion while K is going to be a little later in 2018 (at least that is the way I interpreted the K data). The presentation said some data would be available prior to 2018 but could the company state any numerical data prior to top line results? Not sure about this one point.
No puff, no overhype, just basic, professional presentation that should raise the status of IPIX in the financial community.
(3)
(0)
